A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN-Filo in Infants Aged 4-11 Months in Guinea and Sierra Leone
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
Most Recent Events
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 02 Aug 2022 Planned primary completion date changed from 28 Jun 2022 to 31 Aug 2022.
- 07 Jun 2022 Planned End Date changed from 31 Jul 2022 to 9 Sep 2022.